Conatus Pharmaceuticals Inc (CNAT) announced its most recent quarterly financial results on Wednesday, Mar-15-2017. CNAT reported $-0.35 earnings per share for the quarter, missing the analyst consensus estimate by $-0.02. Analysts had a consensus of $-0.33. During the same quarter in the previous year, the company posted $-0.30 EPS.
Based on several research reports , Company shares were Reiterated by Stifel on Mar 16, 2017 to “Buy”, Firm has raised the Price Target to $ 9 from a previous price target of $7 .Company shares were Reiterated by H.C. Wainwright on Dec 20, 2016 to “Buy”, Firm has raised the Price Target to $ 18 from a previous price target of $9 .Company shares were Reiterated by Stifel on Dec 20, 2016 to “Buy”, Firm has raised the Price Target to $ 7 from a previous price target of $5 .
Several company insiders have filed Insider transactions , on Apr 10, 2015, Daniel L Kisner (director) purchased 4,000 shares at $5.75 per share price.
Conatus Pharmaceuticals Inc opened for trading at $4.65 and hit $5.01 on the upside on Wednesday, eventually ending the session at $4.91, with a gain of 6.05% or 0.28 points. The heightened volatility saw the trading volume jump to 4,72,154 shares. Company has a market cap of $128 M.
Conatus Pharmaceuticals Inc. is a biotechnology company focused on the development and commercialization of medicines to treat liver disease. The Company’s lead compound emricasan is an orally active pan-caspase protease inhibitor designed to reduce the activity of human caspases which are enzymes that mediate inflammation and apoptosis. It is conducting a clinical program to demonstrate the therapeutic benefit of emricasan in patients with chronic liver disease across the spectrum of liver disease including liver cirrhosis (LC); liver cirrhosis with portal hypertension (PH); post-orthotopic liver transplant (POLT) recipients with reestablished liver fibrosis post-transplant as a result of recurrent hepatitis C virus (HCV) infection who have achieved a sustained viral response (SVR) following HCV antiviral therapy (POLT-HCV-SVR) and non-alcoholic fatty liver disease (NAFLD) including patients with inflammatory and/or fibrotic non-alcoholic steatohepatitis (NASH).